Follistatin 344 (95%)

Follistatin 344 1mg is suited for research teams and TGF-β superfamily signaling laboratories investigating activin ligand binding kinetics, myostatin receptor pathway inhibition dynamics, and downstream SMAD signaling cascade marker characterization in controlled preclinical models. Scientists examining follistatin isoform-specific ligand sequestration parameters, activin receptor type II binding interaction dynamics, and downstream SMAD2/3 phosphorylation pathway marker expression will find Follistatin 344 relevant to mechanistic TGF-β superfamily ligand interaction pharmacology study designs.

Research programs requiring a structurally defined follistatin isoform reference compound for comparative ligand binding investigations alongside Follistatin 315 or other TGF-β superfamily modulator compounds benefit from Follistatin 344’s distinct heparan sulfate proteoglycan binding domain profile, which influences tissue localization dynamics and ligand sequestration interaction parameters in preclinical experimental models. Laboratories studying myostatin signaling pathway inhibition, activin-mediated SMAD cascade suppression dynamics, and follistatin isoform-dependent ligand neutralization kinetics in skeletal muscle cell, gonadal tissue, and neural preclinical experimental models will find Follistatin 344 well-suited to multi-arm TGF-β superfamily signaling study designs. Novera supplies Follistatin 344 1mg sourced from USA GMP-certified manufacturing facilities, with each vial COA-verified for purity and sequence identity to approximately 95%.

Activin Receptor Ligand Binding Kinetics and Competitive Sequestration Studies

Follistatin 344 supports in vitro investigation of activin and myostatin ligand binding affinity parameters, competitive receptor occupancy dynamics, and downstream SMAD2/3 phosphorylation cascade suppression in activin receptor type IIA and IIB preclinical cell line experimental models. Researchers characterizing follistatin concentration-dependent ligand neutralization kinetics, receptor binding competition interaction parameters, and downstream pathway inhibition endpoint dynamics use Follistatin 344 as a primary reference compound for TGF-β superfamily ligand sequestration pharmacology study designs.

Downstream SMAD Signaling Cascade Characterization

Laboratories studying TGF-β superfamily signal transduction use Follistatin 344 to quantify downstream molecular marker activity across SMAD2/3 phosphorylation inhibition endpoints, transcriptional regulatory marker expression suppression dynamics, and activin receptor-mediated cascade attenuation characterization in controlled preclinical model systems. Multi-arm protocols comparing Follistatin 344-mediated downstream SMAD pathway inhibition profiles with those produced by Follistatin 315 or other TGF-β superfamily modulators support mechanistic characterization of isoform-dependent differences in downstream signaling endpoint response patterns.

Myostatin Pathway Inhibition and Signaling Research

Follistatin 344 enables preclinical investigation of myostatin ligand sequestration dynamics, ActRIIB receptor pathway inhibition marker expression, and downstream SMAD cascade suppression in skeletal muscle cell experimental models. Research examining myostatin-mediated transcriptional regulatory marker activity, follistatin concentration-dependent pathway inhibition kinetics, and downstream anabolic signaling pathway marker characterization uses Follistatin 344 as a mechanistically defined ligand sequestration reference compound for TGF-β superfamily skeletal muscle signaling study designs.

Comparative Follistatin Isoform Molecular Endpoint Studies

Follistatin 344’s heparan sulfate proteoglycan binding domain enables multi-arm comparative study designs examining how isoform-specific tissue localization dynamics produce different local vs. systemic downstream SMAD pathway inhibition marker patterns relative to Follistatin 315. Research quantifying isoform-dependent molecular endpoint differences across activin and myostatin ligand sequestration kinetics, receptor binding competition parameters, and downstream transcriptional regulatory marker suppression dynamics contributes to mechanistic understanding of follistatin isoform biology across shared TGF-β superfamily downstream pathway systems.

Preparation Guidelines

Reconstitute lyophilized Follistatin 344 1mg with sterile bacteriostatic water using standard sterile laboratory technique. Reconstitution volume should be determined based on the target experimental working concentration specified by the study design. Given the 1mg vial format, precise calibration of reconstitution volume is particularly important to ensure accurate working concentration preparation across all experimental protocol phases; document each reconstitution step in accordance with institutional research record-keeping standards. Use calibrated laboratory equipment throughout all preparation steps.

Storage Conditions

Store lyophilized glycoprotein at 2–8°C, protected from light and moisture, prior to reconstitution. Avoid exposure to repeated freeze-thaw cycling to preserve follistatin structural integrity and ligand binding activity. Following reconstitution, maintain refrigeration at 2–8°C; reconstituted material remains stable for approximately 2–4 weeks under appropriate storage conditions. This product does not require cold-chain shipping, but immediate refrigeration upon receipt is recommended to preserve glycoprotein sequence integrity throughout the protocol period. Each vial supplied by Novera includes COA documentation and handling guidance.

Protocol Duration Guidelines

Preclinical TGF-β superfamily signaling pathway studies using Follistatin 344 span observation periods determined by experimental objectives — from acute ligand binding kinetics and short-term SMAD cascade suppression characterization studies through extended multi-week downstream transcriptional regulatory marker progression and isoform-dependent localization dynamics protocols. Monitor activin receptor pathway activity markers, downstream SMAD2/3 phosphorylation inhibition dynamics, myostatin pathway suppression endpoint expression, and follistatin concentration-dependent ligand sequestration parameters at defined experimental intervals throughout the observation period, in accordance with institutional laboratory standards.

USA GMP-Certified Supply via Novera

Novera supplies Follistatin 344 1mg sourced from USA GMP-certified manufacturing facilities, independently verified to approximately 95% purity by third-party COA documentation. Each vial confirms glycoprotein sequence identity, purity grade, and batch-specific quality control data — providing research laboratories with consistent, research-grade follistatin isoform material for advanced TGF-β superfamily ligand interaction pharmacology and SMAD signaling pathway research.

• CAS: N/A
• Chemical Formula: N/A
• Molecular Weight: 3780 g/mol
• Synonyms: FST, Activin-Binding Protein
• Shelf life: 24 months from the manufacturing date.

Activin and Myostatin Ligand Sequestration Profile

Follistatin 344 binds activin and myostatin ligands with high affinity, neutralizing their availability for TGF-β superfamily receptor engagement in preclinical experimental models. This ligand sequestration mechanism prevents activin and myostatin from binding activin receptor type IIA and IIB, suppressing downstream SMAD2/3 phosphorylation cascade activation and associated transcriptional regulatory marker expression. The ligand sequestration profile enables researchers to investigate TGF-β superfamily pathway inhibition dynamics, downstream SMAD cascade suppression endpoint characterization, and activin receptor occupancy competition parameters under defined follistatin concentration conditions in controlled preclinical model systems.

Isoform-Specific Heparan Sulfate Proteoglycan Binding Dynamics

Follistatin 344 contains a C-terminal heparan sulfate proteoglycan binding domain absent from the Follistatin 315 isoform, producing distinct tissue localization dynamics and extracellular matrix interaction parameters in preclinical experimental models. This isoform-specific structural feature influences the spatial distribution of ligand sequestration activity, enabling researchers to investigate how follistatin isoform-dependent localization differences modify local vs. systemic activin and myostatin pathway inhibition marker patterns. Comparative study designs employing Follistatin 344 alongside Follistatin 315 support systematic isoform-dependent molecular endpoint differentiation across shared downstream SMAD cascade marker systems.

USA GMP-Certified Supply via Novera

Novera supplies Follistatin 344 1mg sourced from USA GMP-certified manufacturing facilities, independently verified to approximately 95% purity by third-party COA documentation. Each vial confirms glycoprotein sequence identity, purity grade, and batch-specific quality control data — providing research laboratories with consistent, research-grade follistatin isoform material for advanced TGF-β superfamily ligand interaction pharmacology and SMAD signaling pathway research.